Announcements Trials
Browse Landscape

Status

Recruiting 10Not yet recruiting 3Withdrawn 1No longer available 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Recurrence 1Leukemia 1

Interventions

Suspensions 2Powders 2trametinib 1talquetamab 1taletrectinib 1sotorasib 1ruxolitinib 1revumenib 1omburtamab I-131 1leronlimab 1gallium maltolate 1dabrafenib 1ceritinib 1capmatinib 1asparaginase erwinia chrysanthemi recombinant 1apalutamide 1Standard of Care 1Paclitaxel 1Nivolumab 1HMPL-013 1Docetaxel 1Asparaginase 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × revumenib × 1 year × Clear all
NCT05918913 2025-09-05

Expanded Access Program for Revumenib

Syndax Pharmaceuticals

No longer available
1 FDA
Other hematologic neoplasm

Leukemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡